¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ o*7`r~  
tZR %s  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© 1*aw~nY0  
2 F3U,}  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© #% PnZ /  
:4]^PB@dl  
1.Co-stimulators (or co-stimulating molecules) %dMq'j  
4J3cQ;z  
2.NK-kB J8[N!qDCj  
~Aul 7[IH  
3.Immunoglobulin superfamily C<Q;3w`#1j  
L=W8Q8 hf  
4.antigen-presenting cell (APC) {VqcZhqy/l  
\Ub=Wm\  
5.death domain Qzbelt@Wx  
N<V,5  
6.CCR and CXCR 8w &A89  
h^#K4/  
7.Lectin (or mitogen) ni$7)YcF  
w@U`@})r.  
8.Clusters of differentiation, CD) Q$_S/d%*  
*G)=6\  
9.B7 family ^DZ(T+q,  
3(|8gWQ  
10.Cytotoxic T lymphocyte, CTL) V<f76U)  
FL -yt  
11.IL-15 and IL-15 receptor (IL-15R) VY }?Nb<&  
=sVB.P  
12.MHC restriction W ~sP7&sp  
'LY.7cW  
13.Affinity-chromatography {VOLUC o 4  
T@c{5a  
14.Cyctosprin A, CsA qF!oP  
7I>@PV N  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) fba QXM  
F)x^AJi e  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© Ic_>[E?k  
zX+NhT TB  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 ^F @z +q  
 f,utA3[  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ U2  0@B`<  
l_ /q/8-l  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ 8RS=Xemds  
=m{]Xep  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© hiKgV|ZD  
Q9v OY8  
ÃâÒßѧרҵ£º |y+<|fb,a  
iXl6XwWT%8  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ + k1|+z zS  
X.)caF^j  
Ïû»¯ÄÚ¿Æ£º Qs(WyP#  
5.st!Lp1  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ 7}+U;0,)  
3R!?r^h  
ѪҺ²¡Ñ§×¨Òµ£º t#pF.!9=  
~V,~' W  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÍøÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»